Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLAMDANK study of dapagliflozin in MASLD with CKD without diabetes
jRCTs051250059Recruiting
- Sponsor
- Japan Strategic Medical Administration Research Center
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dapagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD) (2 arms), sponsored by Japan Strategic Medical Administration Research Center. Primary endpoint: Change in alanine aminotransferase at 24 weeks. Started Nov 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCTs051250059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250059.